Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: The estrogen threshold hypothesis

Gonadotropin-releasing hormone agonists induce a reversible hypogonadotropic hypogonadal environment. Leiomyomas are common, estrogen-sensitive, benign neoplasms that decrease in size by 40% to 50% during gonadotropin-releasing hormone agonist treatment. During gonadotropin-releasing hormone agonist...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of obstetrics and gynecology 1990-10, Vol.163 (4), p.1114-1119
Hauptverfasser:	Friedman, Andrew J., Lobel, Susan M., Rein, Mitchell S., Barbieri, Robert L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Buserelin - administration & dosage Buserelin - analogs & derivatives Buserelin - therapeutic use Estradiol - blood estrogen threshold hypothesis Estrogens - blood Estrogens - therapeutic use Female GnRH agonist Gonadotropin-Releasing Hormone - administration & dosage Gonadotropin-Releasing Hormone - analogs & derivatives Gonadotropin-Releasing Hormone - therapeutic use Goserelin Hormones. Endocrine system Humans hysterectomy Leiomyoma - drug therapy Leiomyoma - pathology Leiomyoma - surgery Leuprolide Medical sciences Middle Aged myomectomy Pharmacology. Drug treatments Pilot Projects Preoperative Care Progestins - therapeutic use Time Factors uterine leiomyomas Uterine Neoplasms - drug therapy Uterine Neoplasms - pathology Uterine Neoplasms - surgery Uterus - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!